Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ALK positive
i
Other names:
NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
238
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
EML4-ALK fusion (27)
ALK fusion (23)
EML4-ALK variant 3 (8)
STRN-ALK fusion (5)
ALK-HIP1 fusion (4)
EML4-ALK L1196M (4)
FN1-ALK fusion (4)
NPM1-ALK F1174C (4)
NPM1-ALK fusion (4)
EML4-ALK variant 1 (3)
NPM1-ALK I1171N (3)
NPM1-ALK I1171T (3)
NPM1-ALK L1196Q (3)
RANBP2-ALK fusion (3)
SLC8A1-ALK fusion (3)
ALK-EML4_V5 (2)
ALK-HLA-DRB1 fusion (2)
CAD-ALK fusion (2)
CARS1‐ALK fusion (2)
CLTC-ALK fusion (2)
CMTR1-ALK fusion (2)
DCTN1-ALK fusion (2)
EML4-ALK C1156Y (2)
EML4-ALK G1202R (2)
EML4-ALK G1269A (2)
EML4-ALK I1171S (2)
EML4-ALK variant 2 (2)
HIP1-ALK I1171N (2)
KIF5B-ALK fusion (2)
LMO7-ALK fusion (2)
ACVR1-ALK fusion (1)
ALK-DCHS1 fusion (1)
ALK-EML4_V1 (1)
ALK-EML4_V2 (1)
ALK-EML4_V3 (1)
ALK-EML4_V5a (1)
ALK-KIF5B fusion (1)
ALK-LIMS1 fusion (1)
ALK-PPFIBP1 fusion (1)
ALK-ROS1 fusion (1)
CCDC6-ALK fusion (1)
CCDC85A-ALK fusion (1)
CLIP4-ALK fusion (1)
COX7A2L-ALK fusion (1)
CTNND1-ALK fusion (1)
CUX1-ALK fusion (1)
Chr t(2;17)(p23;q23) CLTC/ALK (1)
Chr t(2;5)(p23;q35) NPM1/ALK (1)
EML4-ALK + ALK-PEX13 (1)
EML4-ALK E13;A20 (1)
EML4-ALK F1174C (1)
EML4-ALK I1171T (1)
EML4-ALK S1206Y (1)
EML4-ALK fusion + ALK-FEZ2 fusion (1)
EML4-ALK fusion + ALK-SSH2 fusion (1)
EML4-ALK fusion + ARID2-ALK fusion (1)
EML4-ALK fusion + CDK15-ALK fusion (1)
EML4-ALK variant 3a (1)
EML4-ALK variant 3b (1)
EML4_E13-ALK_E19 fusion (1)
EML4_E20-ALK_E19 fusion (1)
EML4_E6-ALK_E18(V3) (1)
EML6-ALK fusion + FBXO11-ALK fusion (1)
ERC1-ALK fusion (1)
GHR-ALK fusion (1)
HIVEP1-ALK fusion (1)
KANK4-ALK fusion (1)
KIDINS220-ALK fusion (1)
KIF13A-ALK fusion (1)
KLC1-ALK fusion (1)
KLHL31-LRRC1-ALK fusion (1)
LINC01173-ALK fusion + LOC388942-ALK fusion (1)
LOC101927285-ALK fusion (1)
LTBP1-ALK fusion (1)
LTBP1-ALK fusion + HIP1-ALK fusion (1)
LTBP1_E2-ALK_E11 fusion (1)
MPRIP-ALK fusion (1)
MRPS9-ALK fusion (1)
MYH9-ALK + ALK-WDR43 (1)
NBEA-ALK fusion + EML4-ALK fusion (1)
NKAIN2-ALK fusion (1)
NPM-ALK fusion (1)
PRKCB-ALK fusion (1)
PTH2R-ALK fusion (1)
RANBP2-ALK + TMEM217-ALK (1)
SDK1-ALK fusion (1)
SETD2-ALK fusion + EML4-ALK fusion (1)
SPECC1L‑ALK fusion (1)
STRN exon 2-ALK exon 20 fusion (1)
TFG-ALK fusion (1)
TNIP2-ALK fusion (1)
TOGARAM2-ALK fusion (1)
UGP2-ALK fusion (1)
CDK15-ALK fusion (0)
EML6-ALK fusion (0)
FBXO11-ALK fusion (0)
EML4-ALK fusion (27)
ALK fusion (23)
EML4-ALK variant 3 (8)
STRN-ALK fusion (5)
ALK-HIP1 fusion (4)
EML4-ALK L1196M (4)
FN1-ALK fusion (4)
NPM1-ALK F1174C (4)
NPM1-ALK fusion (4)
EML4-ALK variant 1 (3)
NPM1-ALK I1171N (3)
NPM1-ALK I1171T (3)
NPM1-ALK L1196Q (3)
RANBP2-ALK fusion (3)
SLC8A1-ALK fusion (3)
ALK-EML4_V5 (2)
ALK-HLA-DRB1 fusion (2)
CAD-ALK fusion (2)
CARS1‐ALK fusion (2)
CLTC-ALK fusion (2)
CMTR1-ALK fusion (2)
DCTN1-ALK fusion (2)
EML4-ALK C1156Y (2)
EML4-ALK G1202R (2)
EML4-ALK G1269A (2)
EML4-ALK I1171S (2)
EML4-ALK variant 2 (2)
HIP1-ALK I1171N (2)
KIF5B-ALK fusion (2)
LMO7-ALK fusion (2)
ACVR1-ALK fusion (1)
ALK-DCHS1 fusion (1)
ALK-EML4_V1 (1)
ALK-EML4_V2 (1)
ALK-EML4_V3 (1)
ALK-EML4_V5a (1)
ALK-KIF5B fusion (1)
ALK-LIMS1 fusion (1)
ALK-PPFIBP1 fusion (1)
ALK-ROS1 fusion (1)
CCDC6-ALK fusion (1)
CCDC85A-ALK fusion (1)
CLIP4-ALK fusion (1)
COX7A2L-ALK fusion (1)
CTNND1-ALK fusion (1)
CUX1-ALK fusion (1)
Chr t(2;17)(p23;q23) CLTC/ALK (1)
Chr t(2;5)(p23;q35) NPM1/ALK (1)
EML4-ALK + ALK-PEX13 (1)
EML4-ALK E13;A20 (1)
EML4-ALK F1174C (1)
EML4-ALK I1171T (1)
EML4-ALK S1206Y (1)
EML4-ALK fusion + ALK-FEZ2 fusion (1)
EML4-ALK fusion + ALK-SSH2 fusion (1)
EML4-ALK fusion + ARID2-ALK fusion (1)
EML4-ALK fusion + CDK15-ALK fusion (1)
EML4-ALK variant 3a (1)
EML4-ALK variant 3b (1)
EML4_E13-ALK_E19 fusion (1)
EML4_E20-ALK_E19 fusion (1)
EML4_E6-ALK_E18(V3) (1)
EML6-ALK fusion + FBXO11-ALK fusion (1)
ERC1-ALK fusion (1)
GHR-ALK fusion (1)
HIVEP1-ALK fusion (1)
KANK4-ALK fusion (1)
KIDINS220-ALK fusion (1)
KIF13A-ALK fusion (1)
KLC1-ALK fusion (1)
KLHL31-LRRC1-ALK fusion (1)
LINC01173-ALK fusion + LOC388942-ALK fusion (1)
LOC101927285-ALK fusion (1)
LTBP1-ALK fusion (1)
LTBP1-ALK fusion + HIP1-ALK fusion (1)
LTBP1_E2-ALK_E11 fusion (1)
MPRIP-ALK fusion (1)
MRPS9-ALK fusion (1)
MYH9-ALK + ALK-WDR43 (1)
NBEA-ALK fusion + EML4-ALK fusion (1)
NKAIN2-ALK fusion (1)
NPM-ALK fusion (1)
PRKCB-ALK fusion (1)
PTH2R-ALK fusion (1)
RANBP2-ALK + TMEM217-ALK (1)
SDK1-ALK fusion (1)
SETD2-ALK fusion + EML4-ALK fusion (1)
SPECC1L‑ALK fusion (1)
STRN exon 2-ALK exon 20 fusion (1)
TFG-ALK fusion (1)
TNIP2-ALK fusion (1)
TOGARAM2-ALK fusion (1)
UGP2-ALK fusion (1)
CDK15-ALK fusion (0)
EML6-ALK fusion (0)
FBXO11-ALK fusion (0)
›
Related tests:
VENTANA ALK (D5F3) CDx Assay (13)
VENTANA ALK (D5F3) CDx Assay (13)
Associations
(73)
News
Trials
Search handles
@AndresFCardonaZ
@CwynKate
@DrJFriedberg
@DrViteri
@Dr_Ivanoncologo
@FilippoPietran4
@FuenteApolo
@JackWestMD
@Latinamd
@MLPOncoData
@MPishvaian
@StephenVLiu
@Tony_Calles
@VivekSubbiah
@ajumathew_
@cczielinski
@christine_lovly
@chulkimMD
@diegoadiazg
@drkpavithran
@gerryhanna
@lindamahj
@oncoOuLungCA
@smbenlazar
@tehfem
@weldeiry
Search handles
@AndresFCardonaZ
@CwynKate
@DrJFriedberg
@DrViteri
@Dr_Ivanoncologo
@FilippoPietran4
@FuenteApolo
@JackWestMD
@Latinamd
@MLPOncoData
@MPishvaian
@StephenVLiu
@Tony_Calles
@VivekSubbiah
@ajumathew_
@cczielinski
@christine_lovly
@chulkimMD
@diegoadiazg
@drkpavithran
@gerryhanna
@lindamahj
@oncoOuLungCA
@smbenlazar
@tehfem
@weldeiry
Filter by
Latest
10ms
Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer - @JTOonline (N=46) ⬆️central obesity from 27-47% ➡️ as pts get treated for years, weight gain is a serious AE #lcsm @ALKPositiveinc https://t.co/FJlfh8BgKv (@Latinamd)
10 months ago
Clinical
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Alecensa (alectinib)
11ms
Early breakfast with @ALKPositiveinc discussing the needs of our patients with ALK positive NSCLC #ASCO23 @ASCO @IASLC (@NarjustFlorezMD)
11 months ago
Clinical
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
11ms
✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “ALK-positive lung cancer: a moving target” by, @DrJaimeLaurel @JessicaJLinMD & #AliceTShaw. Find it here👇 https://t.co/PgDvca9RLc https://t.co/NZcXj7QElT (@NatureCancer)
11 months ago
Review
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
1year
Resistance mechanisms in ALK fusion-positive lung cancer https://t.co/mjdAblRY0I (@MLPOncoData)
1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK fusion
1year
🩸 Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study. Q: With an 18% 12-months VTE incidence, should thromboprophylaxis be recommended upon ALK+ diagnosis? #lcsm https://t.co/Duep8S5c1a (@Tony_Calles)
1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK rearrangement
1year
ALK-positive lung cancer: a moving target https://t.co/4aM3d0zRGI (@AndresFCardonaZ)
1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive
1year
Lorlatinib Induces Rapid and Durable Response in Refractory Anaplastic Lymphoma Kinase–Positive Large B-Cell Lymphoma | JCO Precision Oncology https://t.co/eAxXw1WY2y (@VivekSubbiah)
1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Lorbrena (lorlatinib)
1year
30 yo F with ALK positive NSCLC with 4 BM. Treated with Lorlatinib with excellent response since 9/2022. Oligo persistent left frontal brain met. RX with SRS now? or only if progression? @SamuelChaoMD @GauravMarwahaMD @DrRoyHerbstYale @Mat_Guc @jryckman3 @drdavidpalma (@PhilBlumenfeld)
1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Lorbrena (lorlatinib)
1year
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC) https://t.co/upV1jYqRkR (@DrViteri)
1 year ago
Clinical • Metastases
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Alecensa (alectinib)
1year
The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review. https://t.co/csFNo4SWNW #radonc #srs #LCSM in the majority of cases the quality of life must the main target of the treatment strategy. (@FuenteApolo)
1 year ago
Clinical • Review • HEOR
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
ALK positive
1year
🔥NEW REVIEW ARTICLE @NatureCancer “ALK-positive lung cancer: a moving target” – by @JessicaJLinMD @DrJaimeLaurel #AliceShaw. https://t.co/PgDvca9RLc https://t.co/nmxsw9elQF (@NatureCancer)
1 year ago
Review
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
1year
ALK-positive lung cancer: a moving target | Nature Cancer https://t.co/UPKXMlmk9V (@lindamahj)
1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive
1year
Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings. @JTOonline DOI 👇🏻 https://t.co/RkoeT3NC14 #nsclc #lcsm #alk #targetedtherapy #rwd (@diegoadiazg)
1 year ago
Clinical • Real-world evidence • Real-world
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
1year
Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings - JTO Clinical and Research Reports https://t.co/TOOSpx1GV9 (@tehfem)
1 year ago
Clinical • Real-world evidence • Real-world
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
1year
ALK-positive large B-cell lymphoma, a rare B-cell lymphoma expressing ALK https://t.co/V1EyCZl025 (@smbenlazar)
1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive
over1year
No v, got covid once. Took HCQ prophylactic. Stage 4 lung cancer ALK positive DX 3 years ago. No rad or chemo to date. (@satguy1963)
over 1 year ago
Metastases
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
hydroxychloroquine
over1year
News in brief: 3-year findings from the CROWN trial confirm the long-term benefits of lorlatinib for treatment-naïve, advanced ALK-positive NSCLC regardless of baseline brain metastases, say @bensolomon1 (@PeterMacCC) @JulienMazieres et al @LancetRespirMed https://t.co/DJ6YyKcCiJ (@MM_Oncology)
over 1 year ago
Metastases
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Lorbrena (lorlatinib)
over1year
ALK-positive large B-cell lymphoma, a rare B-cell lymphoma expressing ALK https://t.co/V1EyCZkscx #DLBCL #lymsm (@smbenlazar)
over 1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive
over1year
Efficacy & safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study - The Lancet Respiratory Medicine @bensolomon1 https://t.co/g4yj8Z3cG1 (@VivekSubbiah)
over 1 year ago
Clinical • Metastases
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Xalkori (crizotinib) • Lorbrena (lorlatinib)
over1year
Early View | Haematologica Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma https://t.co/IaYDH2exv9 (@CwynKate)
over 1 year ago
Clinical • Combination therapy
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Xalkori (crizotinib) • vinblastine
over1year
During a Targeted Oncology case-based roundtable event, Benjamin Levy, MD, discussed the current targeted treatment options that target lung cancers that are positive for ALK rearrangements. @hopkinskimmel @benlevylungdoc https://t.co/gYtz8b0Acl (@TargetedOnc)
over 1 year ago
Clinical
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK rearrangement
over1year
Assessment of Alectinib vs Ceritinib in ALK-Positive NSCLC in Phase 2 Trials and Real-world Data https://t.co/d6Ab7XUi0p via @JAMANetworkOpen part of @JAMANetwork (@VivekSubbiah)
over 1 year ago
Clinical • Real-world evidence
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Alecensa (alectinib) • Zykadia (ceritinib)
over1year
Leukemic phase of ALK-positive anaplastic large cell lymphoma | ASH Image Bank | American Society of Hematology https://t.co/7ansdb70DC #ASHImageBank (@smbenlazar)
over 1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive
over1year
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) https://t.co/BFljX1kxWD (@tehfem)
over 1 year ago
Clinical
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Alecensa (alectinib) • Zykadia (ceritinib) • Alunbrig (brigatinib)
over1year
Patient-Reported Outcomes From the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive Non-Small Cell Lung Cancer - #LCSM #ALK https://t.co/sUe8ePio8k (@Tony_Calles)
over 1 year ago
Clinical • Patient reported outcomes
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Xalkori (crizotinib) • Lorbrena (lorlatinib)
over1year
Lorlatinib improved PFS and reduced 12-month cumulative incidence of central nervous system progression compared with crizotinib in patients with advanced ALK-positive NSCLC irrespective of brain metastases at baseline. @bensolomon1 #lcsm https://t.co/3nrbKSsZU0 (@OncLive)
over 1 year ago
Clinical
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Xalkori (crizotinib) • Lorbrena (lorlatinib)
over1year
Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell #lungcancer receiving alectinib. Pls. visit @ESMO_Open by @myESMO https://t.co/WD7MOZ3Qot (@cczielinski)
over 1 year ago
Clinical • Adverse events
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Alecensa (alectinib)
over1year
In patients with advanced ALK-positive NSCLC with brain metastases, first-line lorlatinib induced a 12-month PFS rate of 78% compared with 22% on crizotinib and 78% vs 45%, respectively, for those without. @bensolomon1 #lcsm https://t.co/v9YaXUi0Jh (@OncLive)
over 1 year ago
Clinical
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Xalkori (crizotinib) • Lorbrena (lorlatinib)
over1year
Thank you for bringing awareness. Stop the stigma. Anyone with lungs can get lung cancer. I am ALK Positive and because of research I’m still here after 5 years. (@DaisyAlkie)
over 1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive
over1year
Research delivers hope. #Research does this by expanding the reach of #PrecisionMedicine for people living with ALK-positive lung cancer. It's why Dr Justin Gainor believes #MoreResearchMoreLife. #LCAM #LCSM #hope @JustinGainor #lungcancer (@ALKLungCancer)
over 1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive
over1year
Assessment of Alectinib vs Ceritinib in ALK-Positive NSCLC in Phase 2 Trials and Real-world Data https://t.co/pBY9UPRVDs via @JAMANetworkOpen part of @JAMANetwork (@VivekSubbiah)
over 1 year ago
Clinical • Real-world evidence
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Alecensa (alectinib) • Zykadia (ceritinib)
over1year
#Pembrolizumab monotherapy given in the first-line setting continued to demonstrate durable clinical benefit vs chemotherapy in patients with PD-L1–positive, locally advanced/metastatic #NSCLC without EGFR/ALK alterations. #lcsm | @GilbertodeCas13 @Icesp_ https://t.co/lwMGiYujvo (@TargetedOnc)
over 1 year ago
Clinical
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Keytruda (pembrolizumab)
over1year
An interesting review showed that #Brigatinib effectively treats patients with #ALK-positive non-small cell #lungcancer. https://t.co/o8ca77lXR9 (@Dr_Ivanoncologo)
over 1 year ago
Clinical • Review
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Alunbrig (brigatinib)
over1year
#TumorBoardTuesday 🔬🧬We kicked off #LungCancerAwarenessMonth with a discussion on ALK positive #NSCLC led by @LeciaSequist! ➡️Here's this week's case 🎀 👉🆓 #CME credit by answering 3 quick❓ ALL CME 🔗: https://t.co/63osUKM6ij CME eval🔗: https://t.co/pM93oTpEm7 (@TumorBoardTues)
over 1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive
over1year
1/3 #TumorBoardTuesday Take🏠msgs: #ALK positive #NSCLC ✅5% of NSCLC; esp young, 🚭 ✅Brain mets ~ 30% at dx ✅BEFORE WBRT, get NGS if feasible ✅ALK+ brain mets= responsive to CNS-penetrant TKI 📚We captured @LeciaSequist’s discussion in this moment: https://t.co/T4rbMwLehd (@JohnEbbenMDPhD)
over 1 year ago
Next-generation sequencing
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
over1year
📢 Let’s kick off #LungCancerAwarenessMonth & join #TumorBoardTuesday!! 🫁@LeciaSequist brings us through testing & treating ALK positive #NSCLC 👇🏽Join us!👇🏽 📱Weigh in how YOU’D treat 🧾Bring citations 📊check polls 🔁RT 👩🏻⚕️tag peers 🏆🆓CME @MPishvaian @JohnEbbenMDPhD (@TumorBoardTues)
over 1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive
over1year
Set a ⏲ to join us here on #TumorBoardTuesday!! 📅 Tues 11.01.22 at 8pm ET 👩🏻⚕️ @LeciaSequist 📰 ALK positive #NSCLC #LungCancer 🫁 While we finalize the case, collect FREE #CME (AMA & MOC) 👉🏽 https://t.co/63osUKLysL 👈🏼#OncTwitter (@TumorBoardTues)
over 1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive
over1year
What is the probability of ALK IHC positive but not truly ALK disease (false positive IHC)? #lungcancer @JackWestMD @LeciaSequist @APassaroMD (@ajumathew_)
over 1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive
over1year
Very informative & worthwhile day for the Mum of a daughter Kay diagnosed with alk positive NSCLC in 2016 aged 17 (@AileenMurgatro1)
over 1 year ago
ALK (Anaplastic lymphoma kinase)
|
ALK positive
over1year
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) https://t.co/PVbPEodjYI (@VivekSubbiah)
over 1 year ago
Clinical
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Alecensa (alectinib) • Zykadia (ceritinib) • Alunbrig (brigatinib)
over1year
Great progress in EGFR and ALK positive lung cancer, but a number of emerging clincial scenarios to consider and address posed by @JackWestMD (@gerryhanna)
over 1 year ago
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
ALK positive
over1year
For PD-L1 positive and EGFR/ALK wild type NSCLC, it is highly possible that neoadjuvant IO is better than adjuvant IO. (@JoeChangMD)
over 1 year ago
Clinical
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • ALK positive • EGFR wild-type • ALK wild-type • EGFR positive
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login